Caris Life Sciences, Inc. (CAI) AI Stock Analysis

• Market Cap: $8.77B
• Dividend Yield: N/A
• Average Volume (3M): 728.28K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 1,769
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.08
• Shares Outstanding: 281,224,120
• 10 Day Avg. Volume: 691,794
• 30 Day Avg. Volume: 728,283
• PEG Ratio: -0.52
• Price to Book (P/B): -2.85
• Price to Sales (P/S): 17.30
• P/FCF Ratio: -28.11
• Enterprise Value/Market Cap: 0.82
• Enterprise Value/Revenue: 13.88
• Enterprise Value/Gross Profit: 22.65
• Enterprise Value/Ebitda: -83.58
• 1Y Price Target: $40.40
• Price Target Upside: 67.70% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $24.00 ▼(-0.37% Downside)

The overall stock score is primarily influenced by significant financial challenges and bearish technical indicators. However, the recent earnings call provided a positive outlook with record revenue growth and improved profitability, partially offsetting the negative financial and technical aspects.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong demand for Caris's molecular profiling services, enhancing its competitive position in precision medicine.

Improved Gross Margins

Higher gross margins reflect improved operational efficiency and cost management, contributing to sustainable profitability.

Strong Balance Sheet

A strong cash position provides strategic flexibility for future investments in technology and product development, supporting long-term growth.

Negative Factors

Financial Instability

Ongoing financial instability, marked by negative cash flows and high leverage, poses risks to Caris's ability to sustain operations and invest in growth.

Challenges in Pharma Revenue

Sequential decline in pharma revenue highlights potential volatility and dependency on specific projects, impacting revenue stability.

Complex MRD Approval Process

The complex approval process for MRD products may delay market entry, affecting the company's ability to capitalize on new product opportunities.

Caris Life Sciences, Inc. Business Overview & Revenue Model

Company Description

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.

How the Company Makes Money

Caris Life Sciences generates revenue through the provision of its molecular profiling services to healthcare providers, hospitals, and oncologists. The company charges fees for its tests, which analyze tumor samples to identify genetic alterations and biomarkers that can inform treatment decisions. Key revenue streams include payments for individual tests, subscription models for ongoing services, and partnerships with pharmaceutical companies for drug development and clinical trials. Additionally, Caris may benefit from collaborations with academic institutions and research organizations, which can lead to increased usage of its profiling services in research and clinical practice.

Caris Life Sciences, Inc. Financial Statement Overview

Summary

Caris Life Sciences, Inc. faces significant financial challenges with declining profitability, negative cash flows, and high leverage, indicating financial instability and risks to future growth.

Income Statement

Caris Life Sciences, Inc. has experienced a decline in profitability over recent years, with negative net profit margins and EBIT margins indicating operational challenges. Revenue growth has been inconsistent, with a notable decline in 2020. The company has struggled to maintain positive margins, reflecting difficulties in managing costs relative to revenue.

Balance Sheet

The balance sheet shows significant financial leverage, with a negative stockholders' equity and a high debt-to-equity ratio in earlier years. This indicates potential financial instability and risk. The return on equity has been positive but low, suggesting limited returns for shareholders given the high leverage.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows in recent years, indicating liquidity challenges. The free cash flow to net income ratio is positive, suggesting some efficiency in converting income to cash, but the overall cash flow position remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2020	Dec 2019
Income Statement
Total Revenue	519.15M	412.26M	306.13M	258.49M	294.01M	416.54M
Gross Profit	318.25M	178.78M	89.31M	80.02M	184.16M	200.51M
EBITDA	-86.22M	-182.95M	-260.80M	-245.89M	254.46M	248.30M
Net Income	-150.05M	-281.89M	-341.42M	-320.83M	27.73M	31.01M
Balance Sheet
Total Assets	984.57M	343.73M	412.90M	717.42M	2.61B	2.90B
Cash, Cash Equivalents and Short-Term Investments	755.49M	66.15M	121.59M	409.62M	132.54M	46.46M
Total Debt	426.74M	424.26M	217.27M	270.87M	1.75B	2.10B
Total Liabilities	506.21M	2.84B	2.56B	2.42B	1.91B	2.21B
Stockholders Equity	478.36M	-2.50B	-2.14B	-1.70B	702.24M	693.24M
Cash Flow
Free Cash Flow	27.20M	-253.64M	-298.42M	-327.96M	57.57M	-65.14M
Operating Cash Flow	38.38M	-245.20M	-276.10M	-285.71M	277.02M	254.00M
Investing Cash Flow	-11.17M	52.93M	214.77M	-282.99M	-33.97M	-271.87M
Financing Cash Flow	661.59M	200.29M	10.13M	10.45M	-249.88M	-108.48M

Caris Life Sciences, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CAI	47 Neutral	$8.77B	―	―	―	―	―
BOLT	45 Neutral	$9.67M	-0.19	-81.97%	―	-46.88%	34.83%
MSPR	40 Underperform	$996.00K	―	―	―	-8.57%	-52.17%
SNSE	40 Underperform	$10.95M	-0.41	-67.47%	―	―	9.63%
INAB	34 Underperform	$7.49M	-0.16	-189.72%	―	―	70.57%

Caris Life Sciences, Inc. Corporate Events

Caris Life Sciences Reports Record Revenue Growth

Caris Life Sciences’ recent earnings call painted a picture of robust financial health and strategic growth, marked by record-breaking revenue and improved profitability metrics. The company celebrated significant achievements, including a strong balance sheet and increased average selling price (ASP). However, challenges such as pharma revenue fluctuations and the intricate process for MRD approval were also acknowledged.

Caris Life Sciences Reports Strong Q3 2025 Growth

Caris Life Sciences, Inc., headquartered in Irving, Texas, is a pioneering AI TechBio company specializing in precision medicine and molecular profiling services to advance healthcare through innovative diagnostic solutions.

Caris Life Sciences Reports Strong Q2 2025 Results

Caris Life Sciences, Inc., a leading AI TechBio company in the precision medicine sector, focuses on developing innovative diagnostic solutions through comprehensive molecular profiling and advanced AI technologies. In its second quarter of 2025 financial results, Caris Life Sciences reported a significant revenue increase of 81.3% to $181.4 million compared to the same period last year. The company also achieved a positive Adjusted EBITDA of $16.7 million and positive net cash flow from operating activities of $7.3 million, indicating strong operational performance.